MASPORE Protocol for Leukemia
I cannot identify a specific protocol called "MASPORE" in the current medical literature or established treatment guidelines for leukemia. This acronym does not appear in any major leukemia treatment guidelines from NCCN, ESMO, ELN, or other authoritative sources in the provided evidence.
What You May Be Looking For
If you are seeking standard leukemia treatment protocols, the established approaches depend on leukemia type:
For Acute Myeloid Leukemia (AML)
The standard induction regimen is "7+3" consisting of cytarabine 100-200 mg/m²/day continuous infusion for 7 days with daunorubicin 60-90 mg/m² or idarubicin 10-12 mg/m²/day for 3 days 1. For CD33+ patients, adding gemtuzumab ozogamicin to the 7+3 regimen (7+3+GO) has shown improved 6-year overall survival by 20.7% in core binding factor AML 1.
For FLT3-mutated AML, use standard cytarabine and daunorubicin plus midostaurin 50 mg twice daily on days 8-21 1.
For therapy-related AML or AML with myelodysplasia-related changes, CPX-351 (liposomal daunorubicin/cytarabine) has improved 2-year overall survival by 18.8% 1, 2.
For Acute Promyelocytic Leukemia (APL)
For low- or intermediate-risk APL (WBC ≤10,000/mcL), ATRA combined with arsenic trioxide (ATO) is now standard of care, achieving complete remission rates exceeding 90% 3. This regimen consists of ATRA 45 mg/m² plus ATO 0.15 mg/kg daily until complete remission, then ATO 5 days per week for 4 weeks every 8 weeks for 4 courses, and ATRA daily for 2 weeks every 4 weeks for 7 courses 3.
For Acute Lymphoblastic Leukemia (ALL)
For adults <65 years with Ph-negative ALL, use multiagent regimens based on vincristine, anthracyclines, corticosteroids, and L-asparaginase 4. For pediatric patients, standard-risk cases receive 3-drug induction without anthracyclines, while high-risk cases receive 4-drug induction including anthracyclines 4.
Common Pitfalls
Do not confuse protocol acronyms: Established protocols include AIDA (ATRA plus idarubicin), VDT-PACE (for multiple myeloma, not leukemia), and TRAMPCOL (historical 8-drug regimen from 1977) 3, 5.
Verify the exact protocol name with your institution or the referring physician, as local protocols may have unique naming conventions not found in published literature.
If treating elderly or unfit patients, hypomethylating agents (azacitidine or decitabine) or venetoclax-based regimens are preferred over intensive chemotherapy 1.